Presentations
The attorneys of BSKB regularly present lecture on an array of intellectual property topics.
-
November 20, 2024
The Appeal Review Panel and Ex parte Chamberlain
-
October 23, 2024
Resolution of Arthrex Decision and DOC New Rules
-
October 9, 2024
Recent Developments in Obviousness-Type Double Patenting
-
September 25, 2024
Overview of USPTO’s July 2024 guidance on patent subject matter eligibility concerning AI-related inventions
-
May 22, 2024
PureCircle USA Inc. v. SweeGen, Inc. (Fed. Cir. 2024)
-
May 8, 2024
Guidance for AI-Assisted Inventions
-
April 3, 2024
Patent Inventorship: How Difficult is it to Add a Joint Inventor to an Issued Patent?
-
February 28, 2024
Sonos v. Google - The Next Generation of Prosecution Laches
-
February 14, 2024
PETITIONER ASKS SUPREME COURT: Has The Diehr Holding Been Overruled?
-
November 15, 2023
The means-plus-function issue in WSOU Investments LLC v. Google LLC
-
October 25, 2023
In re Cellect: Patent Term Adjustment (PTA) under 35 USC § 154; Patent Term Extension (PTE) under 35 USC § 156; Obviousness-Type Double Patenting (OTDP); and Terminal Disclaimers (TD)
-
September 20, 2023
A review of the analogous art test: Sanofi v. Mylan, No. 21-1981 (Fed. Cir. May 9, 2023)
-
May 24, 2023
UCB v. Actavis Laboratories – Relying on range limitations in claims to distinguish from prior art
-
May 10, 2023
Discussion of 35 U.S.C. § 103 Rejections and “Known Technique” Rationale
-
March 29, 2023
Can an Article of Manufacture be an Abstract Idea?
-
March 8, 2023
Duty of Disclosure and Duty of Reasonable Inquiry
-
February 22, 2023
Pushing Back against Obviousness Rejections Unsupported by Evidence and Lacking Reasoned Explanations: A discussion of In re Google LLC.
-
February 8, 2023
LKQ CORP, KEYSTONE V. GM GLOBAL No. 2021-2348 (Fed. Cir. 2023)
-
November 16, 2022
Overview of AI Application and Related Issues
-
November 2, 2022
Biogen International GmbH et al. v. Mylan Pharmaceuticals Inc.: Another hurdle for Pharmaceutical Patents